Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01064-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Masum Miah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden. Hauptthemen laut MEDLINE: Rhinovirus, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Vetenskapsrådet (VR), Stiftelsen Forska Utan Djurförsök (Swedish Fund for Research Without Animal Experiments).
Abstract (Originalsprache)
Screening a library of 1,200 preselected kinase inhibitors for anti-human rhinovirus 2 (HRV-2) activity in HeLa cells identified a class of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) as effective virus blockers. These were based on the 4-anilinoquinazoline-7-oxypiperidine scaffold, with the most potent representative AZ5385 inhibiting the virus with EC 50 of 0.35 µM. Several structurally related analogs confirmed activity in the low µM range, while interestingly, other TKIs targeting EGFR lacked anti-HRV-2 activity. To further probe this lack of association between antiviral activity and EGFR inhibition, we stained infected cells with antibodies specific for activated EGFR (Y1068) and did not observe a dependency on EGFR-TK activity. Instead, consecutive passages of HRV-2 in HeLa cells in the presence of a compound and subsequent nucleotide sequence analysis of resistant viral variants identified the S181T and T210A alterations in the major capsid VP1 protein, with both residues located in the vicinity of a known hydrophobic pocket on the viral capsid. Further characterization of the antiviral effects of AZ5385 showed a modest virus-inactivating (virucidal) activity, while anti-HRV-2 activity was still evident when the inhibitor was added as late as 10 h post infection. The RNA copy/infectivity ratio of HRV-2 propagated in AZ5385 presence was substantially higher than that of control HRV indicating that the compound preferentially targeted HRV progeny virions during their maturation in infected cells. Besides HRV, the compound showed anti-respiratory syncytial virus activity, which warrants its further studies as a candidate compound against viral respiratory infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Göteborg, Sweden.
- Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Mölndal, Sweden.
- Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Cambridge, United Kingdom.
- HTS Discovery Sciences, BioPharmaceutical R&D, AstraZeneca, Macclesfield, United Kingdom.
ORCID-Profile: Joanna S Said, Thomas Lundbäck, Edward Trybala
Förderung
- Vetenskapsrådet (VR)
- Stiftelsen Forska Utan Djurförsök (Swedish Fund for Research Without Animal Experiments)
Zitieren
APA
Miah, M., Davis, A. M., Hannoun, C., Said, J. S., Fitzek, M., Preston, M., Smith, D., Uwamariya, C., Kärmander, A., Lundbäck, T., Bergström, T., & Trybala, E. (2024). Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01064-23
Vancouver
Miah M, Davis AM, Hannoun C, Said JS, Fitzek M, Preston M, et al. Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01064-23
BibTeX
@article{Miah2024,
author = {Miah, Masum and Davis, Andrew M and Hannoun, Charles and Said, Joanna S and Fitzek, Martina and Preston, Marian and Smith, Dave and Uwamariya, Colores and Kärmander, Ambjörn and Lundbäck, Thomas and Bergström, Tomas and Trybala, Edward},
title = {Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01064-23}
}
EUVIMED